Empowering People to be Ambassadors of their Own Health Since 1997.


Weekly News

Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week.  Topics include all stories related to hepatitis C  as well as personal stories and events.

HCV News

Week Ending 10/12/2015

Injecting Hope: UC doctor takes on heroin epidemic with needle exchange program

‘Judith Feinberg is drawn to a mess. Knowing that helps explain why the UC infectious disease doc has boxes of Narcan — the “Lazarus” drug used to revive someone after a deadly overdose of heroin — piled high over her desk on the third floor of Holmes Hospital. Each lifesaving kit will make its way into the hands of a user by way of the mobile needle exchange she started last year.’

Results from Merck’s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet

‘Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naïve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection.’

Harvey Alter Receives 2015 Fries Prize for Improving Health

‘Harvey Alter, M.D., M.A.C.P., today received the 2015 Fries Prize for Improving Health at the Centers for Disease Control and Prevention (CDC) for his life-saving research and leadership in translating science into practice, which has prevented millions of new infections and cases of disease and death from Hepatitis B virus (HBV), Hepatitis C virus (HCV) and HIV infections.’

Delaying HCV therapy among PWID leads to advanced liver diseases

‘In a new meta-analysis and systematic review, researchers from New York University found that people who injected drugs who were also positive for hepatitis C virus infection were likely to develop liver problems later in life if left untreated, including cirrhosis and hepatocellular carcinoma, according to published findings in The International Journal of Drug Policy.’

Surge in Youth HCV Presents Hepatologists With Tough Choices

‘Recently Mark S. Sulkowski, MD, of the John Hopkins University School of Medicine, in Baltimore, saw a teenage patient who had contracted hepatitis C after starting to shoot up as a 12-year-old. The case is but one in a spike of new infections with the hepatitis C virus (HCV) being driven largely by an epidemic of injection drug use, particularly among adolescents and young adults, according to the Centers for Disease Control and Prevention.’

High prevalence of hepatitis B and poor knowledge on hepatitis B and C viral infections among barbers: a cross-sectional study of the Obuasi municipality, Ghana

‘Barbers, while shaving, may be accidentally exposed to the blood and bodily fluids of their customers increasing their risk of contraction of HBV and HCV infections. Hence, this study aimed at examining the prevalence and knowledge of barbers on HBV and HCV infections in the Obuasi municipality of Ghana.’

Dose Modification Not Needed in Coadministration of an HIV, HCV Tx

‘Coadministration of tenofovir alafenamide-based single tablet regimens for HIV with ledipasvir/sofosbuvir does not require dose modification, results from a drug-drug interaction study presented at IDWeek 2015 has shown. About one-third of HIV patients have a co-infection with hepatitis C virus (HCV).’

Daklinza Hepatitis C Drug Seeks Label Expansion

‘The FDA is considering expanding the use for a drug currently indicated as a chronic hepatitis C (HCV) treatment. Bristol-Myers Squibb’s 3 supplemental New Drug Applications (sNDAs) for daclatasvir (Daklinza) for use with sofosbuvir with or without ribavirin were recently granted priority review status. The 3 applications seek a label expansion for treating patients co-infected with HCV and human immunodeficiency virus (HIV), patients with advanced cirrhosis, and patients with post-liver transplant recurrence of HCV.’

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)